Asepsis announces the patent pending Momenta-Dose™, a parenteral injection device designed to administer an injection solely by a user’s applied force and subsequent momentum. This autogenic momentum injector is industry unique as it does not use any commercial auto-injector technology such as gases, springs or any other stored kinetic energy.
Asepsis announces the patent pending Safe-T-Fuse™. This industry unique infusion bag allows the contents of a standard vial to be quickly introduced to an integrated diluent reservoir without the use of any sharps or additional components. The Safe-T-Fuse™ allows the contents of a vial to be reconstituted during a user controlled period and subsequently its reconstituted solution delivered to the internal infusion solution reservoir through a user controlled metered amount and period.
Asepsis announces the patented Safe-T-Dose®, Calibrated Drug Delivery™ injection kit. Safe-T-Dose® is designed to offer the same combinatorial and passive safety features of the Pedia-Dose® yet contains standard non reduced dosage medication.
Asepsis announces the patent pending Momenta-Dose™ PFS, a parenteral injection device designed to accept standard disposable syringes and configured for a user’s specific dosage and injection depth, thus providing for an economical personalized injection. The deivice administers an injection solely by a user’s applied force and subsequent momentum. This autogenic momentum injector is industry unique as it does not use any commercial auto-injector technology such as gases, springs or any other stored kinetic energy. The device is adapted to accept standard disposable syringes
Asepsis announces the patented Pedia-Dose® Calibrated Drug Delivery™ injection kit. Pedia-Dose® is specifically designed for ultra-precise small volume injections for neonates and pediatric patients. The combinatorial kits’ design enables the most cost efficient reduced volume pediatric or neonatal medicinal delivery. The Safe-T-Syringe™ contained within the Pedia-Dose® is volume and indicia calibrated to patient weight, BSA or other characteristic. The Syringe offers enhanced patient specific low incremental calibration enabling better visibility and accuracy for precision low volume, low patient weight injections.
Asepsis announces the patent pending, Vi-Injection kit. This combinatorial medicinal injection kit is designed for enhancing the safety and accuracy of a self-injection by a vision impaired (VI) patient. The kit is comprised of a Vi-Syringe™ and all other required components for the medicinal injection with an outer packaging in braille and enhanced visual markings. The components within the kit are also designed with braille or other tactile features as well as enhanced visual numeric indicia. The combined features assist and enhance the self-preparation and administration of the injection by VI patient.
Asepsis announces the patent pending Vi-Syringe™. The Vi-Syringe™ is the world’s first ergonomically designed hypodermic syringe that allows a visually impaired user to independently prepare and administer an injectable medication accurately, solely by the use of tactile indicators.